Bayer defeats Merck in lawsuit over talc liabilities
Send a link to a friend
[April 04, 2023]
By Jonathan Stempel
(Reuters) -A Delaware judge on Monday dismissed Merck & Co's lawsuit
seeking to hold Bayer AG responsible for more talc-related liabilities
stemming from its $14.2 billion purchase of Merck's consumer care
business in 2014.
Vice Chancellor Nathan Cook of the Delaware Chancery Court said the
purchase agreement "clearly and unambiguously" left Merck liable for
claims related to products, including Dr. Scholl's foot powder, sold
before the transaction closed.
The companies face potentially billions of dollars of liability from
lawsuits by consumers alleging that asbestos contained in talc-based
products such as Dr. Scholl's caused cancer.
Merck claimed that its liability ended on Oct. 1, 2021, seven years
after the transaction closed, and sued Bayer after the German company
refused to assume liability.
![](http://archives.lincolndailynews.com/2023/Apr/04/images/ads/current/safetytip_sda_applegate_2023.png)
But the judge called Bayer's interpretation of the purchase agreement
"the only reasonable one," and said letting Merck "dump" cases would
give the Rahway, New Jersey-based company an incentive to prolong or
stall lawsuits.
"Nothing in the (agreement) indicates that the parties intended Bayer to
assume liability for all of Merck's actions for the period during which
it formulated, marketed, and sold the products" at issue, Cook wrote in
a 37-page decision.
![](http://archives.lincolndailynews.com/2023/Apr/04/images/ads/current/charrons_bch_2022.png)
[to top of second column]
|
![](../images/040423PIX/health76.jpg)
Signage is seen at the Merck & Co.
headquarters in Kenilworth, New Jersey, U.S., November 13, 2021.
REUTERS/Andrew Kelly
![](http://archives.lincolndailynews.com/2023/Apr/04/images/ads/current/debbies_lda_032222.png) Merck said it was disappointed with
the decision and planned to appeal.
Bayer welcomed the decision, saying that it expected Merck to "take
full responsibility for the product claims".
"Bayer will continue to defend itself against any further efforts by
Merck to avoid or improperly transfer its liabilities to Bayer," the
company said in a statement.
The $14.2 billion purchase also included Merck's Claritin allergy
medicine and Coppertone sunscreen lines.
Bayer separately inherited liability for litigation over whether the
weedkiller Roundup causes cancer when it spent $63 billion in 2018
to buy Monsanto.
In June 2020, Bayer agreed to settle much of that litigation for
$10.9 billion. As of February 2023, about 109,000 of the 154,000
claims it faced had been settled or deemed ineligible.
The case is Merck & Co v. Bayer AG, Delaware Chancery Court, No.
2021-0838.
(Reporting by Jonathan Stempel in New York; Writing by Friederike
Heine; Editing by Jonathan Oatis and Stephen Coates)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |